Tyra Biosciences 3Q 2026: EPS ($0.74) — 10-Q Summary
Tyra Biosciences reported a wider net loss in 3Q 2026, with R&D costs rising due to dabogratinib trials and headcount growth. Net loss was $51.12M, and diluted EPS was ($0.74). The company has $700.5M in cash, expected to last through 2030. Dabogratinib trials showed initial positive results.
How this was made
The 30-second read
Why it matters
The widened loss and EPS decline suggest near‑term price weakness, but strong cash position and trial progress could support longer‑term upside.
Market read
Primary earnings disclosure for a micro‑cap biotech; relevant for traders tracking biotech earnings and pipeline developments.
What to watch
Cash runway of $700 M through 2030 provides ample liquidity, potentially mitigating short‑term concerns.
Background
Tyra Biosciences is a clinical‑stage biotech developing dabogratinib for rare diseases. The 10‑Q includes trial enrollment updates and cash position.
Ticker impact
Tyra Biosciences filed its 3Q 2026 10‑Q showing a widened net loss and EPS of –$0.74, new data not previously public.
downward pressure as investors price in the widened loss and higher R&D spend
The report reveals a 48% decline in EPS and a 71% increase in net loss, indicating weaker performance than prior quarter.
Market effects
Highlights continued cash burn in biotech R&D, may pressure peer small‑cap biotech valuations.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech sector.
Counterpoint
If the trial data for dabogratinib shows promising early results, the loss may be viewed as a temporary investment in pipeline value.
Key entities
- companyTyra Biosciences
Biotech firm reporting 3Q 2026 results.
- drugdabogratinib
Investigational therapy with ongoing trial activity.
